Careers  |  Sign In  |  Register  |   Twitter

OTC Use of Lovastatin Unlikely

A joint meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic Drugs Advisory Committee voted 10-2, with one abstention, against recommending OTC use of lovastatin 20 mg in patients considered to be at moderate risk of CHD.

References and Resources
FDA news
Click Here to view information.

Division of Over-the-Counter Drug Products, FDA
Consumer Behavior Issues Related To the Marketing of Mevacor OTC
Memorandum
Click Here to view information.

Sponsored by The Doctor’s Channel